Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Primula veris + hyoscyamus niger is an anthroposophic medicinal combination developed by Weleda AG for the treatment of functional cardiovascular disorders and nervous heart complaints. The formulation leverages the pharmacological properties of two botanical extracts: *Primula veris* (cowslip) and *Hyoscyamus niger* (henbane). *Hyoscyamus niger* contains tropane alkaloids, such as hyoscyamine and scopolamine, which act as non-selective muscarinic acetylcholine receptor antagonists, providing sedative and antispasmodic effects that help alleviate anxiety-induced cardiac symptoms. *Primula veris* is traditionally utilized in anthroposophic medicine to stabilize the rhythmic system and support cardiac function. This combination is typically administered as oral drops to manage symptoms like palpitations, heart racing, and sleep disturbances associated with nervous tension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on primula veris + hyoscyamus niger.